Stock Traders Buy High Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of some unusual options trading on Tuesday. Investors bought 6,620 call options on the company. This represents an increase of 173% compared to the typical daily volume of 2,429 call options.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in Sangamo Therapeutics by 58.8% during the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after buying an additional 1,528,600 shares during the period. Wasatch Advisors LP raised its stake in Sangamo Therapeutics by 62.4% during the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after buying an additional 7,734,400 shares during the period. Acadian Asset Management LLC raised its stake in Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after buying an additional 192,385 shares during the period. Marshall Wace LLP raised its stake in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 207,476 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its stake in Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on SGMO shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday. StockNews.com started coverage on Sangamo Therapeutics in a research report on Sunday, July 28th. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $2.67.

Sangamo Therapeutics Stock Up 32.5 %

SGMO stock opened at $1.21 on Wednesday. The business’s fifty day moving average is $0.86 and its 200-day moving average is $0.66. The company has a market cap of $251.95 million, a P/E ratio of -0.88 and a beta of 1.23. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. Research analysts anticipate that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.